Connect With Us

Inside INdiana Business
Subscribe Now Log In
  • Home
  • News
    • Education
    • Health
    • Tech
    • STEM
    • Advanced Manufacturing & Logistics
    • Life Sciences
    • Ag INnovation
    • INPower
  • Videos
  • Big Wigs
    • Submit Big Wigs
  • Events
    • Engage Southwest Indiana – Evansville
    • Engage Northwest Indiana – Valparaiso
    • Engage Greater Lafayette – West Lafayette
    • Engage West Central Indiana – Terre Haute
    • Engage South Bend – Elkhart
    • Engage Northeast Indiana – Fort Wayne
    • Engage Central Indiana – Indianapolis
  • Newsletters
  • Podcasts
  • On-Air
    • TV & Radio Listings
  • Contact
    • About IIB
    • Meet the Team
    • Contact Us
    • Advertise
    • Gift Cards
    • Flagship Stations
    • Gerry’s Message
    • Speaking Engagement Request

Connect With Us

Lilly Strengthens Pipeline With $960M Deal

Wednesday, January 18, 2017 08:21 AM EDT Updated: Wednesday, January 18, 2017 09:44 AM EDT
By Andy Ober
Lilly Strengthens Pipeline With $960M Deal Lilly completed the CoLucid acquisition in March.

Indianapolis-based Eli Lilly and Co. (NYSE: LLY) is acquiring a Massachusetts biopharmaceutical company in a $960 million deal. Lilly says the deal for CoLucid Pharmaceuticals Inc. (Nasdaq: CLCD) will strengthen its pain management portfolio.

CoLucid is developing an oral treatment for migraines. The drug, called lasmiditan, has completed the first of two Phase 3 trials, with the second expected in the second half of the year. The companies say, if the results are positive, U.S. regulatory approval could come next year.

Lilly Chief Executive Officer David Ricks calls the treatment a "novel, first-in-class molecule that could represent the first significant innovation for the acute treatment of migraine in more than 20 years." The treatment was originally discovered at Lilly and out-licensed to CoLucid in 2005. Since then, the Indianapolis company has reorganized its research and development efforts to focus on pain therapeutics, including for migraine.

CoLucid is also collaborating with Pfizer on the development of tanezumab for the treatment of pain from conditions including osteoarthritis and cancer.

The deal comes about two months after Lilly took a major hit to its pipeline. In November, the company announced it would drop further pursuit of a once-promising potential treatment for Alzheimer’s disease. At the time, the company said solanezumab did not achieve "a significant slowing in cognitive decline" for patients compared to placebo. Better news came in December, when the U.S. Food and Drug Administration approved type 2 diabetes treatment Jardiance as a means to reduce the risk of cardiovascular death and and Synjardy XR to help improve blood sugar in adults with type 2 diabetes when used with diet and exercise.

The deal equates to $46.50 per share. It’s expected to close by the end of the first quarter.

Story Continues Below

Most Popular Stories

  • Pacers to sell 15% ownership stake in franchise to billionaire Steven Rales

  • Iconic ‘Hoosiers’ trophy gets new permanent home

  • Deep frozen storage facility opens in Greenfield

  • Startup lands $30M in funding to commercialize cancer imaging agent

  • IndyGo CEO leaving after four years leading transit agency

  • Performance management plays a key role in employee engagement

Perspectives

Performance management plays a key role in employee engagement

Performance management plays a key role in employee engagement

Employee engagement is a catchall term that refers to the degree to which employees are committed to their work and their organization. We all know that engaged employees are more productive, more creative, and more likely to stay with their organization. So, how does performance management impact employee engagement?...

Inside INdiana Business

Inside INdiana Business
A division of IBJ Media

1 Monument Circle, Suite 300
Indianapolis, IN 46204

PHONE: (317) 634-6200

FAX: (317) 263-5060

NEWSLETTER@IIBNEWS.COM

  • Home
  • News
  • Videos
  • Gerry Dick
  • Newsletters
  • On-Air
  • Contact

Copyright © 2023 All Rights Reserved Privacy Policy | Terms of Service